NK vs. PRME, IKT, PLX, ACHL, IZTC, ZIVO, BLUE, CRTX, CYTH, and FNCH
Should you be buying NantKwest stock or one of its competitors? The main competitors of NantKwest include Prime Medicine (PRME), Inhibikase Therapeutics (IKT), Protalix BioTherapeutics (PLX), Achilles Therapeutics (ACHL), Invizyne Technologies (IZTC), ZIVO Bioscience (ZIVO), bluebird bio (BLUE), Cortexyme (CRTX), Cyclo Therapeutics (CYTH), and Finch Therapeutics Group (FNCH). These companies are all part of the "medical" sector.
NantKwest vs. Its Competitors
NantKwest (NASDAQ:NK) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.
Prime Medicine has a net margin of 0.00% compared to NantKwest's net margin of -76,658.58%. NantKwest's return on equity of -56.06% beat Prime Medicine's return on equity.
In the previous week, Prime Medicine had 2 more articles in the media than NantKwest. MarketBeat recorded 2 mentions for Prime Medicine and 0 mentions for NantKwest. Prime Medicine's average media sentiment score of 0.51 beat NantKwest's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media.
NantKwest has higher earnings, but lower revenue than Prime Medicine. NantKwest is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.
NantKwest has a beta of 2.61, indicating that its share price is 161% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.
9.4% of NantKwest shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 71.7% of NantKwest shares are owned by company insiders. Comparatively, 22.9% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Prime Medicine has a consensus target price of $10.08, indicating a potential upside of 228.45%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Prime Medicine is more favorable than NantKwest.
Summary
Prime Medicine beats NantKwest on 10 of the 17 factors compared between the two stocks.
Get NantKwest News Delivered to You Automatically
Sign up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NantKwest Competitors List
Related Companies and Tools
This page (NASDAQ:NK) was last updated on 7/3/2025 by MarketBeat.com Staff
